Metabolomics-Based Elucidation of Therapeutic Mechanism of Luteolin Towards Autism in Children and Relevant Drug-Drug Interaction Risk

被引：0
|
作者：
Sun, Xingzhen [1 ]
Li, Chaoyang [1 ]
Wang, Xiang [1 ]
Zhang, Rongrong [1 ]
Hong, Ze [1 ]
机构：
[1] Nanjing Med Univ, Huaian Peoples Hosp 1, Dept Gen Pediat, Huaian 223300, Jiangsu, Peoples R China
来源：
LATIN AMERICAN JOURNAL OF PHARMACY | 2015年 / 34卷 / 03期
关键词：
autism; drug safety; lutrolin; metabolomics; SPECTRUM DISORDERS; FORMULATION;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Limited understanding for pathogenetic autism spectrum disorders results in the limited drugs for these diseases. In the present study, metabolomics-based analysis method was employed to compare healthy volunteers (n = 10), autism children (n = 10), and luteolin-treated autism children (n = 10). The results showed that autism children exhibited higher long-chain fatty acid-carnitine conjugates than healthy volunteers, indicating the inhibition of fatty acids oxidative process in autism children. The treatment with luteolin significantly decreased the level of long-chain fatty acid-carnitine conjugates. The drug-drug interaction risk between luteolin and zidovudine was furtherly determined, and the results showed that luteolin did not affect the metabolism of these two drugs. In conclusion, metabolomics-based analysis of luteolin-treated autism patients showed that luteolin can reverse autism-induced inhibition of fatty acids metabolism. Additionally, this drug is relatively safe because of none of drug-drug interaction.
引用
收藏
页码：590 / 592
页数：3
相关论文
共 50 条
  • [31] Mechanism-Based Inactivation of CYP2D6 by Phellopterin and Related Drug-Drug Interaction with Metoprolol
    Cheng, Zihao
    He, Yan
    Chen, Yu
    Zhao, Guode
    Liu, Ying
    Zhang, Jingyu
    Li, Ximei
    Ran, Guangyun
    Zhang, Qing
    Peng, Ying
    Li, Weiwei
    Zheng, Jiang
    JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2024, 72 (03) : 1745 - 1755
  • [32] Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole
    Le Merdy, Maxime
    Tan, Ming-Liang
    Sun, Dajun
    Ni, Zhanglin
    Lee, Sue-Chih
    Babiskin, Andrew
    Zhao, Liang
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2021, 46 (01) : 41 - 51
  • [33] Development of a preclinical model for the assessment of the drug-drug interaction potential of mechanism based cytochrome P-450 inactivators
    Scott, DO
    Freyer, AS
    Maurer, TS
    Boer, J
    DeBartolo, D
    Tess, DA
    Wolford, A
    Vage, C
    Zhang, Y
    DRUG METABOLISM REVIEWS, 2004, 36 : 195 - 195
  • [34] A Deep Learning Approach Based on Feature Reconstruction and Multi-dimensional Attention Mechanism for Drug-Drug Interaction Prediction
    Xie, Jiang
    Ouyang, Jiaming
    Zhao, Chang
    He, Hongjian
    Dong, Xin
    BIOINFORMATICS RESEARCH AND APPLICATIONS, ISBRA 2021, 2021, 13064 : 400 - 410
  • [35] Drug-drug Interaction Prediction Method Based on Multi-level Attention Mechanism and Message Passing Neural Network
    Rao, Xiao-Jie
    Zhang, Tong
    Meng, Xian-Bing
    Chen, C.L. Philip
    Zidonghua Xuebao/Acta Automatica Sinica, 2023, 49 (12): : 2507 - 2519
  • [36] Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators
    Hubbs, Jed L.
    Fuller, Nathan O.
    Austin, Wesley F.
    Shen, Ruichao
    Ma, Jianguo
    Gong, Zhen
    Li, Jian
    Mckee, Timothy D.
    Loureiro, Robyn M. B.
    Tate, Barbara
    Dumin, Jo Ann
    Ives, Jeffrey
    Bronk, Brian S.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (07) : 1621 - 1626
  • [37] Prediction of Drug-Drug Interactions Arising From Mechanism-Based Inactivation: Key Input Parameters and Impact on Risk Assessment
    Wong, Simon G.
    CURRENT DRUG METABOLISM, 2011, 12 (09) : 871 - 890
  • [38] A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide
    Huitema, ADR
    Mathôt, RAA
    Tibben, MM
    Rodenhuis, S
    Beijnen, JH
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (03) : 211 - 230
  • [39] SRR-DDI: A drug-drug interaction prediction model with substructure refined representation learning based on self-attention mechanism
    Niu, Dongjiang
    Xu, Lei
    Pan, Shourun
    Xia, Leiming
    Li, Zhen
    KNOWLEDGE-BASED SYSTEMS, 2024, 285
  • [40] Model-Based Drug-Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy
    Cleary, Yumi
    Gertz, Michael
    Grimsey, Paul
    Gunther, Andreas
    Heinig, Katja
    Ogungbenro, Kayode
    Aarons, Leon
    Galetin, Aleksandra
    Kletzl, Heidemarie
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (06) : 1547 - 1557
12345